Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Aberrant B-cell receptor/NF-κB signaling is crucial in B-cell lymphomas like DLBCL.
• Mutations in CD79B, CARD11, NFKBIZ, and MyD88 deregulate NF-κB, but their specific roles are unclear.

Purpose of the Study:

• To functionally investigate the impact of naturally occurring NF-κB mutants on lymphoma development and biology.
• To identify therapeutic vulnerabilities associated with specific mutations in DLBCL.

Main Methods:

• Utilized Eµ-myc transgenic mouse models with hematopoietic stem cells transduced with NF-κB mutants.
• Analyzed lymphoma cell phenotypes, including apoptosis, secretion profiles, and immune-checkpoint mediator expression (PD-L1).
• Assessed therapeutic efficacy of anti-programmed cell death 1 (PD-1) checkpoint blockade.

Main Results:

• Most NF-κB mutants repressed apoptosis, supporting Myc-driven lymphoma.
• CARD11- or MyD88-mutant lymphomas exhibited a macrophage-activating secretion profile and TGF-β-mediated senescence.
• These mutant lymphomas overexpressed PD-L1, evading host adaptive immunity.
• Anti-PD-1 therapy induced T-cell-mediated lysis of senescent lymphoma cells.

Conclusions:

• Specific NF-κB mutations (CARD11, MyD88) confer unique pathogenic principles and therapeutic vulnerabilities in DLBCL.
• Mouse-derived signatures correlate with human DLBCL subgroups, suggesting potential for personalized treatment strategies.
• Functional investigation of mutant-specific dependencies offers insights into DLBCL pathogenesis and treatment.